このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache

2026年6月4日 更新者:Huilin Liu、Beijing Hospital of Traditional Chinese Medicine

Clinical Research on Fire Needling Combined With Filiform Needling for Chronic Migraine With Comorbid Tension-type Headache

The investigators conducted a multicenter, prospective, randomized controlled clinical study to learn whether fire needling combined with filiform needling applied to pericranial muscle tenderness areas can effectively treat chronic migraine with comorbid tension-type headache. The study will also evaluate the safety and long-term efficacy of this therapy. Its main target questions include:

  1. Can fire needling significantly reduce the number of headache days per month?
  2. What is the effect of this therapy on headache intensity, emotional symptoms, and quality of life? The investigators will compare "fire needling at pericranial tender points plus conventional filiform needling" versus "conventional filiform needling alone" to verify whether the key technique of fire needling plus conventional filiform needling provides unique additive value.

Participants will:

  1. Receive treatment twice per week for 8 weeks (either in the experimental group or the control group),attend a follow-up visit at week 24 after enrollment
  2. Keep a headache diary (recording headache frequency, pain intensity, duration, associated symptoms, etc.)
  3. Regularly complete assessments of emotional status, quality of life, and number of pericranial tender points

調査の概要

詳細な説明

Based on international research progress and our preliminary findings, our team proposes that headache episodes in chronic migraine often present with clinical features of tension-type headache. Patients commonly exhibit widespread pericranial muscle tenderness. Integrating the trigemino-cervical complex (TCC) pathway theory and the long-term foundation of acupuncture treatment for tension-type headache, the investigators propose that chronic migraine primarily develops from the comorbidity of migraine and tension-type headache, with pericranial muscle tenderness being a key pathogenic factor and therapeutic target. Fire-needle pinpointing of tender points in pericranial muscles is a key technique for achieving favorable outcomes.

This multicenter randomized controlled trial will enroll 88 patients with chronic migraine comorbid with tension-type headache. They will be randomly allocated in a 1:1 ratio to either the experimental group or the control group via a central randomization system. The experimental group will receive "fire-needle pinpointing of pericranial tender points plus conventional filiform needle acupuncture," while the control group will receive "conventional filiform needle acupuncture" only. Treatment will be administered twice weekly for 8 weeks, with a follow-up period of 24 weeks.

The study will evaluate clinical efficacy and safety by comparing the two groups in terms of headache days, pain intensity, duration, associated symptoms, emotional status, quality of life, number of pericranial tender points, and safety indicators before and after treatment and at the end of the follow-up period. The aim is to confirm that "pericranial muscle tender areas are the key therapeutic target for chronic migraine comorbid with tension-type headache" and that "fire-needle pinpointing is the key technique for this target." The primary outcome will be the internationally recognized headache frequency. Secondary outcomes will include headache intensity, headache-related emotional symptoms, and health-related quality of life. Long-term follow-up will assess sustained effects, with the goal of providing an acupuncture-based treatment strategy to significantly improve the clinical efficacy for chronic migraine.

研究の種類

介入

入学 (推定)

88

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100070
        • Beijing Tiantan Hospital, Capital Medical University
        • コンタクト:
          • baokai Wang
          • 電話番号:86+010+59976611
          • メール:wbk04@126.com
        • 主任研究者:
          • baokai Wang
      • Beijing、Beijing Municipality、中国、100010
        • Beijing Hospital of Traditional Chinese Medicine
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Hui Lin Liu
      • Beijing、Beijing Municipality、中国、100730
        • Capital Medical University Affiliated Beijing Tongren Hospital
        • コンタクト:
        • コンタクト:
          • luquan Chen
        • 主任研究者:
          • luquan Chen

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Meets the diagnostic criteria for tension-type headaches with pericranial tenderness;
  • Meets the diagnostic criteria for chronic migraine;
  • 18 years ≤ age ≤ 65 years;
  • Has sufficient understanding to complete the necessary examinations and tests for the study;
  • Voluntarily joins this study and signs the informed consent form.

Exclusion Criteria:

  • Patients complicated with cluster headache or other primary headaches;
  • Patients with secondary headaches caused by intracranial space-occupying lesions, cranial infections, etc.;
  • Patients complicated with severe heart, liver or kidney impairment, coagulation disorders, infections, severe immunocompromise, or allergic predisposition;
  • Patients with alcohol or drug dependence;
  • Patients who are unable to cooperate with acupuncture treatment;
  • Women who are planning pregnancy, pregnant or breastfeeding;
  • Patients who have received acupuncture treatment within 3 months prior to enrollment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:filiform needling

This point selection protocol follows the international standard acupuncture preventive treatment regimen specified in the Acupuncture Clinical Practice Guideline: Migraine (WFAS 007.8-2023) issued by the World Federation of Acupuncture-Moxibustion Societies (WFAS).

Main Points Baihui (GV20), Shenting (GV24), Fengchi (GB20, bilateral), Benshen (GB13, bilateral), Shuaigu (GB8, bilateral), Taiyang (EX-HN5, bilateral).

Adjuvant Points For Shaoyang headache: add Toulinqi (GB15), Yangbai (GB14), Fubai (GB10), Zulinqi (GB41), Waiguan (TE5), Yanglingquan (GB34).

For Yangming headache: add Touwei (ST8), Hegu (LI4), Neiting (ST44). For Taiyang headache: add Kunlun (BL60), Houxi (SI3). For Jueyin headache: add Taichong (LR3), Qiuxu (GB40). Procedure Fengchi (GB20) is needled 0.5-1 cun toward the nasal tip. All other points are needled perpendicularly. Following the arrival of de qi, even reinforcing-reducing method is applied, with needles retained for 30 minutes.

Selection of acupoints for filiform needle therapy is integrated with the international standard acupuncture preventive treatment protocol for migraine specified in Acupuncture Clinical Practice Guidelines for Migraine issued by the World Federation of Acupuncture-Moxibustion Societies (WFAS 007.8-2023).Treatment was administered twice weekly for 8 weeks.

Main Acupoints:

Baihui (GV20), Shenting (GV24), Fengchi (GB20, bilateral), Benshen (GB13, bilateral), Shuaigu (GB8, bilateral), Taiyang (EX-HN5, bilateral).

Adjunct Acupoints:

For shaoyang headache: add Toulinqi (GB15), Yangbai (GB14), Fubai (GB10), Zulinqi (GB41), Waiguan (SJ5), Yanglingquan (GB34); For yangming headache: add Touwei (ST8), Hegu (LI4), Neiting (ST44); For taiyang headache: add Kunlun (BL60), Houxi (SI3); For jueyin headache: add Taichong (LR3), Qiuxu (GB40).

実験的:fire needling combined with filiform needling
Fire needle prickling was applied to the pericranial tenderness areas, combined with filiform needle acupuncture at meridian points. The acupoint prescription for filiform needle acupuncture was identical to that in the control group.
Fire needling was used to puncture pericranial muscle tenderness areas (including the external occipital protuberance, superior nuchal line, nuchal plane, mastoid process; cervicoscapular areas; epicranial aponeurosis - frontal and temporal regions; upper trapezius, sternocleidomastoid, levator scapulae, temporalis, masseter, and occipitofrontalis muscles) in addition to filiform needling at meridian acupoints (same acupoints as the filiform needling group). Treatment was administered twice weekly for 8 weeks.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment efficacy
時間枠:At week 8 of treatment, and follow-up at week 24 of enrollment
Based on the statistics from the headache diaries completed by patients, it is defined as the proportion of subjects who achieve a reduction in headache days of ≥50% after treatment compared to before treatment.
At week 8 of treatment, and follow-up at week 24 of enrollment

二次結果の測定

結果測定
メジャーの説明
時間枠
Headache days
時間枠:Baseline, at week 8 of treatment, and follow-up at week 24 of enrollment.
Baseline, at week 8 of treatment, and follow-up at week 24 of enrollment.
Headache Duration
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Headache severity
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
The proportion of monthly headache attacks occurring ≤1 time per month
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Migraine-Specific Quality of Life Questionnaire(MSQ) (Version 2.1)
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
This is a 14-item questionnaire that measures how migraines affect a patient's daily life and is a highly reliable and valid instrument. The raw scores are transformed to a 0-100 scale and higher scores reflect greater quality of life.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Hamilton Depression Rating Scale, 24-item (HAMD-24)
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
The HAMD-24 is a clinician-administered scale used to assess the severity of depressive symptoms. It consists of 24 items, most of which are scored from 0 to 4 (0 = absent, 4 = very severe), and a few items are scored from 0 to 2 (0 = absent, 2 = marked). The total score ranges from 0 to 76, with higher scores indicating more severe depression.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Hamilton Anxiety Rating Scale, 14-item
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
The HAMA-14 is a clinician-administered scale used to assess the severity of anxiety symptoms. It consists of 14 items, each scored on a 5-point scale from 0 (not present) to 4 (very severe). The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
The number of tender areas in pericranial muscles and their distribution
時間枠:Baseline, at week 8 of treatment
By palpation
Baseline, at week 8 of treatment
Pericranial muscle tender area tenderness threshold
時間枠:Baseline, at week 8 of treatment
The subject is instructed to relax naturally and sit on a chair with a backrest. The researcher uses an electronic pressure meter (SHSCYQ ZMF-50) to perform standardized assessment and recording of the tender points identified through palpation. A 1 cm² circular probe of the device is placed perpendicularly over the palpated tender point and pressed evenly into the skin at a rate of 0.5 N/s. The subject presses a feedback button as soon as pain is felt, and the pressure value displayed at that moment is recorded. Each tender point is measured three times, with an interval of 10 to 15 seconds between measurements. The average of the three values is calculated as the pressure pain threshold for that tender point.
Baseline, at week 8 of treatment
The status of painkiller intake among subjects
時間枠:Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
Recording of adverse events
時間枠:During the 8-week treatment period
Document adverse events such as needle syncope, hematoma, etc. during acupuncture, along with their grading and management measures.
During the 8-week treatment period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Liu Hui Lin Liu、Beijing Hospital of Traditional Chinese Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2026年5月18日

QC基準を満たした最初の提出物

2026年6月4日

最初の投稿 (実際)

2026年6月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月8日

QC基準を満たした最後の更新が送信されました

2026年6月4日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2026BL02-023-01
  • 2026-2-2233 (その他の助成金/資金番号:Capital's Funds for Health Improvement and Research)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する